A Pilot Study on the Use of Platelet Rich Plasma (PRP) for Facial and Hand Skin Rejuvenation

Exclusion Criteria

• •1. Patients with clinically abnormal platelet count, serum chemistry, or screening laboratory results as reviewed by the Principal Investigator
• •2. Patients who have had any cosmetic procedures meant to address skin aging of face and hands 3 months prior to enrollment
• •3. Patients who have had resurfacing laser on face or hands within one year prior to enrollment
• •4. Patients taking anti-rheumatic disease medication (including methotrexate or other anti-metabolites) within the 3 months prior to study entry
• •5. Patients who are pregnant or currently breast-feeding
• •6. Patients with systemic, rheumatic, or inflammatory disease or who are immunosuppressed
• •7. Patients with ongoing infectious disease, including HIV and hepatitis
• •8. Patients with history of significant cardiovascular, renal, hepatic, endocrine disease, cancer, or diabetes
• •9. Patients participating in a study of an experimental drug or medical device within 30 days of study entry
• •10. Patients with history of platelet disorders, bone marrow aplasia, sepsis, or cancer
• •11. Patients taking anti-aggregating therapy
• •12. Patients on anticoagulant therapy
• •13. Patients with history of keloid formation
• •14. Patients with uncontrolled diabetes
• •15. Patients with active skin disease or skin infection on the intended treatment areas, at baseline